In another deal that highlights the pressures facing companies in the digital health sector, Akili Interactive has agreed to go private in a merger with Virtual Therapeuti
Digital health company Akili is on the brink of its first major expansion beyond the US, partnering with Shionogi to file a localised version of its attention deficit hype
Akili Interactive’s decision to launch a non-prescription version of its digital therapeutic (DTx) for attention-deficit hyperactivity disorder (ADHD) is credited with an
One of the pioneers of the prescription digital therapeutics (DTx) sector, Akili Interactive, has decided to abandon that approach and focus exclusively on a direct-to-con
Akili Interactive has revealed the findings of a trial of its digital therapeutic (DTx) for attention-deficit hyperactivity disorder (ADHD) in adults, suggesting it may be
Akili has started trading publicly today, raising $163 million as a result of its merger with a blank cheque company, saying the cash injection will help fund further development of its vid
Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care" drug for the common skin disorder.
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.